Skip to main content

Vividion Therapeutics Raises $135M in Series C Funding

NEW YORK – Vividion Therapeutics said on Wednesday it has raised $135 million in a Series C financing round led by two new investors, Logos Capital and Boxer Capital of Tavistock Group.

San Diego-based Vividion plans to use the new funding to advance its pipeline of products into the clinic next year. The company's lead candidates are products that target the KEAP1-NRF2 axis and treat NRF2-mutant and NRF2-addicted cancers. The company will also use the funding to advance its drug discovery platform, which focuses on identifying traditionally undruggable targets for cancer and immune disorders.

With the new funding, Vividion will also advance a therapeutic program in partnership with Bristol Myers Squibb that is targeting an undisclosed transcription factor involved in cancer and immunology indications. Additionally, the company has an exclusive license agreement with Roche to use its platform to target novel E3 ligases and develop various oncology and immunology therapeutic targets.

Other new investors that participated in the round include SoftBank Investment Advisers, Avoro Capital Advisors, BlackRock, RA Capital Management, T. Rowe Price Associates, Inc., Surveyor Capital, Woodline Partners, Acuta Capital, and Driehaus Capital Management. The company's existing investors ARCH Venture Partners, BVF Partners, Casdin Capital, Mubadala Capital, Nextech Invest, and Versant Ventures also participated.

"By leveraging our unique platform technologies, we are building a robust pipeline of precision oncology and immunology programs," Vividion CEO Jeffrey Hatfield said in a statement. "We're excited to have attracted such a distinguished group of healthcare investors, whose support will be instrumental in fueling the continued maturation of our broad pipeline, with the intention of beginning to advance programs into the clinic next year."